Abstract:e14574 Background: Immune checkpoint inhibitors (ICIs), targeting the programmed cell death 1 (PD-1), programmed cell death ligand 1 (PD-L1) or cytotoxic T lymphocyte-associated protein 4 (CTLA-4) have demonstrated impressive anti-tumor efficacy in multiple tumors, particularly non-small cell lung cancer (NSCLC). However, only a minority of patients could clinically benefit from the ICIs. Therefore, it is of vital clinical significance to explore underlying predictive biomarkers to identify to identify these most potentially ICIs-benefitable patients. Nuclear pore associated protein 1 ( NPAP1 ) encodes an protein is associated with the nuclear pore complex and has been previously reported as a potential prognostic biomarker for laryngeal, colorectal and lung cancers. However, its role in lung cancer immunotherapy remains unknown. Here we aimed to explore the association between NPAP1 and ICIs. Methods: 165 NSCLC patients from three public immunotherapy cohorts (Hellmann 2018, Miao 2018, and Rizvi 2015 cohort) were included to analyze the association between NPAP1 gene mutation and efficacy of ICI therapy. Genomic, survival and mRNA data of NSCLC patients from the Cancer Genome Atlas (TCGA) database was used to explore the potential mechanisms of anti-tumor immunity. Results: NSCLC patients with NPAP1 mutation were significantly associated with better PFS (HR = 0.37; 95% CI, 0.19-0.71; P = 0.002), objective response rate (ORR, 54.2% vs 28.4%; P = 0.048) and durable clinical benefit (DCB, 75.0% vs 42.6%; P = 0.003) after ICIs therapy, compared with those with wide-type NPAP1 . NPAP1 mutation were associated with increased TMB ( P < 0.001). In the multivariable Cox proportional hazards regression model adjusted by smoking status, PD-L1 expression and TMB, the association between NPAP1 mutation and PFS remained significant (HR = 0.46; 95% CI, 0.23-0.92; P = 0.028). In contrast, no association between NPAP1 mutation and OS (LUAD: P = 0.24 ; LUSC: P = 0.94) or PFS (LUAD: P = 0.3; LUSC: P = 0.72) was observed in TCGA datasets, suggesting that NPAP1 mutation may be a predictive but not a prognostic factor in ICI treatment for NSCLC patients. Based on CIBERSORT-inferred tumor infiltrating lymphocytes from TCGA, NPAP1 mutation was significantly associated with higher activated memory CD4+ T cell and CD8+ T cell. Moreover, NPAP1 mutation was associated with increased TMB ( P < 0.001) and neoantigen load ( P < 0.001) in TCGA. Conclusions: Our results demonstrated that NPAP1 mutation is an underlying classifier that could stratify patients with NSCLC for ICIs. The role of NPAP1 in immunotherapy is needed to be further studied.

YAP1 Mutation As a Novel Predictor of Response to Anti-Pd-1/pd-l1 Treatment in Pan-Cancers.

The Prognostic Value of YAP1 on Clinical Outcomes in Human Cancers

YAP1 as a Novel Negative Biomarker of Immune Checkpoint Inhibitors for EGFR-Mutant Non-Small-Cell Lung Cancer

YAP1 Expression is Associated with Survival and Immunosuppression in Small Cell Lung Cancer

Gene Regulation Network of Prognostic Biomarker YAP1 in Human Cancers: An Integrated Bioinformatics Study

Prognostic Value Of Yes-Associated Protein 1 (Yap1) In Various Cancers: A Meta-Analysis

Comprehensive Analysis of Gene Regulation Network and Immune Signatures of Prognostic Biomarker YAP1 in Pancreatic Cancer

The predictive value of YAP-1 for efficacy of immunotherapy among patients with ES-SCLC.

Analysis of YAP1 Gene As a Potential Immune-Related Biomarker and Its Relationship with the TAZ Expression

YAP1 activation is associated with the progression and response to immunotherapy of non-muscle invasive bladder cancer

Genome-Wide Interrogation Identifies Yap1 Variants Associated With Survival Of Small-Cell Lung Cancer Patients

Data from Genome-Wide Interrogation Identifies <i>YAP1</i> Variants Associated with Survival of Small-Cell Lung Cancer Patients

Yes-associated protein (YAP) in pancreatic cancer: at the epicenter of a targetable signaling network associated with patient survival

Abstract PO3-28-06: YAP1 expression is a good prognostic marker of hormone receptor-positive HER2-negative breast cancer: clinicopathologic analysis using the 21-gene recurrent score

Genome-Wide Interrogation Identifies <i>YAP1</i> Variants Associated with Survival of Small-Cell Lung Cancer Patients

Yes-Associated Protein 1 As a Novel Prognostic Biomarker for Gastrointestinal Cancer: A Meta-Analysis

YAP1 amplification as a prognostic factor of definitive chemoradiotherapy in nonsurgical esophageal squamous cell carcinoma.

YAP1 suppression inhibits autophagy and improves the efficacy of anti-PD-1 immunotherapy in hepatocellular carcinoma

High Cytoplasmic YAP1 Expression Predicts a Poor Prognosis in Patients with Colorectal Cancer

NPAP1 mutation as an indicator stratified patients benefit from immune checkpoint inhibitors in NSCLC.

YAP1 expression in colorectal cancer confers the aggressive phenotypes via its target genes